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Many SIV isolates can employ the orphan receptor GPR15 as coreceptor for efﬁcient entry into
transfected cell lines, but the role of endogenously expressed GPR15 in SIV cell tropism is largely
unclear. Here, we show that several human B and T cell lines express GPR15 on the cell surface,
including the T/B cell hybrid cell line CEMx174, and that GPR15 expression is essential for SIV infection
of CEMx174 cells. In addition, GPR15 expression was detected on subsets of primary human CD4þ ,
CD8þ and CD19þ peripheral blood mononuclear cells (PBMCs), respectively. However, GPR15þ PBMCs
were not efﬁciently infected by HIV and SIV, including cells from individuals homozygous for the
defective D32 ccr5 allele. These results suggest that GPR15 is coexpressed with CD4 on PBMCs but that
infection of CD4þ , GPR15þ cells is not responsible for the well documented ability of SIV to infect
CCR5 blood cells.
& 2012 Elsevier Inc. All rights reserved.Introduction
The human immunodeﬁciency viruses, HIV-1 and HIV-2, cause
acquired immunodeﬁciency syndrome (AIDS) in humans and the
simian immunodeﬁciency virus from macaques (SIVmac) induces
an AIDS-like illness in experimentally infected Asian macaques
(Clavel et al., 1987; Gallo et al., 1984; Letvin et al., 1985). In
contrast, more than 40 African non-human primate species are
naturally infected with SIVs and usually do not develop disease
(Sharp and Hahn, 2010), with the exception of SIVcpz infected
chimpanzees (Keele et al., 2009). HIV-1 is responsible for the AIDS
pandemic, while HIV-2 is endemic in parts of Western Africa and
is phylogenetically and antigenically closely related to SIVmac
(Cohen et al., 2008; de Silva et al., 2008).ll rights reserved.
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n).
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nsburg, Germany.Infectious host cell entry of HIV and SIV is mediated by the
viral envelope protein (Env), which consists of a surface subunit,
gp120, and a transmembrane subunit, gp41 (Tilton and Doms,
2010). The Env proteins of all HIV and SIV isolates characterized
to date use CD4 as the primary receptor for host cell entry,
although several HIV-2 and SIV isolates can infect target cells in a
CD4-independent fashion (Edinger et al., 1997b; Endres et al.,
1996; Martin et al., 1997; Reeves et al., 1999) and CD4-indepen-
dent HIV-1 variants have been generated in vitro (Dumonceaux
et al., 1998; Haim et al., 2011; Hoffman et al., 1999; Kolchinsky
et al., 1999). Binding of gp120 to CD4 induces conformational
changes in gp120, which lead to the creation or exposure of a
conserved coreceptor binding site (Rizzuto et al., 1998). Corecep-
tor engagement subsequently activates gp41 mediated fusion of
the viral envelope and the cellular membrane, thereby allowing
delivery of the viral genetic information and proteins into the host
cell cytoplasm (Harrison, 2008; Steffen and Po¨hlmann, 2010).
Coreceptor tropism varies between HIV and SIV: HIV-1 and
HIV-2 can use CCR5 (R5-tropic viruses), CXCR4 (X4-tropic viruses)
or both (R54-tropic viruses) for entry into primary human T
cells (Alkhatib et al., 1996; Chen et al., 1997; Choe et al., 1996;
Deng et al., 1996; Doranz et al., 1996; Dragic et al., 1996; Feng
M. Kiene et al. / Virology 433 (2012) 73–8474et al., 1996; Rucker et al., 1997; Sol et al., 1997), while SIV isolates
employ CCR5 but not CXCR4 (Chen et al., 1997; Edinger et al.,
1997a; Hill et al., 1997; Kirchhoff et al., 1997; Rucker et al., 1997),
with rare exceptions (Chen et al., 1998; Schols and De Clercq,
1998). In addition, many HIV-2 and SIV isolates can use the
orphan receptor GPR15/BOB and other 7-transmembrane G-pro-
tein-coupled receptors for efﬁcient infection of cell lines trans-
fected to ectopically express these receptors (Blaak et al., 2005;
Chen et al., 1997; Deng et al., 1996; Edinger et al., 1997a; Elliott
et al., 2012; Farzan et al., 1997; Hill et al., 1997; Morner et al.,
1999; Rucker et al., 1997). Usage of GPR15 and other alternative
coreceptors has also been documented for some HIV-1 isolates
(Deng et al., 1996; Farzan et al., 1997; Po¨hlmann et al., 1999a;
Rucker et al., 1997; Zhang et al., 2001), but robust usage of
alternative coreceptors is less frequent among HIV-1 compared to
HIV-2 and SIV.
Selective knock-out of GPR15 usage by a point mutation in the
SIVmac V3-loop is compatible with efﬁcient viral spread and
pathogenesis (Po¨hlmann et al., 1999b), suggesting that usage of
GPR15 in addition to CCR5 is not important for SIVmac infection
of rhesus macaques. However, SIVs can infect PBMCs from human
donors homozygous for the D32 ccr5 defect allele (Dean et al.,
1996; Huang et al., 1996; Samson et al., 1996), suggesting that
engagement of alternative coreceptors can support CCR5- inde-
pendent SIV spread in primary target cells (Forte et al., 2003;
Zhang et al., 2000). Whether GPR15 is expressed by CD4þ human
blood cells and contributes to CCR5-independent SIV infection of
human PBMCs is currently unknown.
We report that human B and T cell lines express GPR15 and
that GPR15 usage is essential for SIVmac infection of the T/B
hybrid cell line CEMx174. GPR15 was also detected on a subset of
primary human CD4þ PBMCs. However, only a fraction of the
SIVmac infected PBMCs expressed GPR15, indicating that the
contribution of GPR15þ cells to SIV ampliﬁcation in human
PBMCs is minor.Results
SIVmac239 uses human GPR15 and CXCR6 with similar efﬁciency as
CCR5 for entry into transfected cells
Previous studies showed that SIVmac239 can use the human
alternative coreceptors GPR15 and CXCR6 for efﬁcient host cell
entry into coreceptor transfected cells (Deng et al., 1997; Farzan
et al., 1997). To conﬁrm and extend these results, we analyzed
SIVmac239 utilization of a panel of alternative coreceptors. For
this, 293T cells, which are CD4 and non-permissive to HIV or SIV
infection, were transiently cotransfected with plasmids encoding
the human CD4 receptor and either one of the potential corecep-
tors CXCR4, CXCR6, CCR2, CCR3, CCR5, GPR1 or GPR15, all of
human origin. The transfected cells were then infected with
luciferase-encoding env-deﬁcient HIV-1 NL4–3 pseudovirus bear-
ing the Env proteins of murine leukemia virus (MLV), HIV-1 NL4–
3, SIVmac239 or no envelope protein (Fig. 1A). Pseudotypes
bearing the MLV Env infected all cells with comparable high
efﬁciency, independent of coreceptor expression (Fig. 1A). The X4-
tropic HIV-1 NL4–3 Env protein facilitated efﬁcient entry into
cells transfected to coexpress CD4 and CXCR4, as expected, but
inefﬁcient infection of all other cells tested was also detected, an
observation in line with the previously documented endogenous
expression of low amounts of CXCR4 by 293T cells (Wilen et al.,
2011) (Fig. 1A). Finally, the SIVmac239 Env mediated robust and
comparable infection of cells coexpressing CD4 and either CCR5,
CXCR6 or GPR15. Coexpression of GPR1 also allowed for SIV-
mac239 driven entry, although with markedly reduced efﬁciencycompared to CCR5, CXCR6 and GPR15, while infection of cells
coexpressing the CCR2, CCR3 and CXCR4 coreceptors was close to
or within background levels (Fig. 1A).
The efﬁcient SIVmac239 Env-driven entry into GPR15 and
CXCR6 transfected cells might be due to particularly high expres-
sion of these receptors in transfected cells. To investigate this
possibility and to conﬁrm our results with authentic SIVmac239,
we constructed CCR5, GPR15 and CXCR6 variants with an
N-terminal AU-1 tag and compared expression and coreceptor
function of these receptors. All constructs were expressed to
roughly comparable levels (Fig. 1B), as determined by FACS
analysis, and allowed entry of SIVmac239, encoding luciferase in
place of nef, with similar efﬁciency as the wt coreceptors (Fig. 1C),
indicating that the N-terminal tag did not interfere with protein
folding. In contrast, none of the other coreceptors tested facili-
tated efﬁcient SIVmac239 entry and all cells were comparably
susceptible to infection with an env-defective SIVmac239 vector
pseudotyped with the G-protein of VSV (VSV-G) (Fig. 1C). Thus,
GPR15 and CXCR6 support efﬁcient SIVmac239 entry into trans-
fected cells, in keeping with published work (Chen et al., 1997;
Edinger et al., 1997a; Feng et al., 1996; Kirchhoff et al., 1997;
Rucker et al., 1997), and efﬁcient coreceptor activity is not due to
exceedingly high expression of these coreceptors compared
to CCR5.GPR15 is expressed on lymphoid cell lines
The robust usage of GPR15 by SIVmac239 for entry into
transfected cells prompted the question whether the virus can
employ endogenous GPR15 for infection of susceptible cell lines.
Expression of GPR15 protein in cell lines has previously not been
investigated and was assessed employing a commercially avail-
able mouse monoclonal antibody. In order to assure speciﬁcity of
GPR15 detection, we ﬁrst analyzed potential cross-reactivity of
the anti-GPR15 antibody with other 7-transmembrane G-protein
coupled receptors. For this, we transiently transfected 293T cells
with different coreceptors and subjected the transfected cells to a
two-step antibody staining with either mouse anti-GPR15 or an
isotype matched control (IgG2b) antibody and a Cy5-labeled anti-
mouse secondary antibody. Reactivity of the anti-GPR15 antibody
with the cells transfected to express CXCR4, CXCR6, CCR2, CCR3,
CCR5 or GPR1 was within the background range observed for the
isotype matched control antibody (Fig. 2A). In contrast, staining of
GPR15-transfected 293T cells resulted in strong ﬂuorescent sig-
nals and a shift from 5 to 186 in geometric mean channel
ﬂuorescence (Fig. 2A).
We next determined if GPR15 is expressed on the human CD4-
positive T cell lines C8166-SEAP (Means et al., 1997), Jurkat, PM-1,
CEM-T4 and Sup-T1 CD4-negative. In addition, the T/B hybrid cell
line CEMx174 (Salter et al., 1985), which expresses GPR15 mRNA
(Farzan et al., 1997; Kirchhoff et al., 1997), and a CEMx174
derivate, engineered to express CCR5 (CEMx174 R5, (Hsu et al.,
2003)), were examined for the presence of GPR15 protein. Robust
GPR15 expression was detected on CEMx174, CEMx174 R5 and
PM-1 cells, all of which are susceptible to SIVmac infection (Lusso,
2006; Marzi et al., 2007; Po¨hlmann et al., 1999b), but not on the
other T cell lines tested. One exception were C8166-SEAP T cells
which yielded signals slightly above background in four indepen-
dent experiments. In order to analyze if GPR15 is also expressed
by other lymphoid cell lines, we expanded our analysis to the B
cell lines Raji, NC37, BCBL-1, DG75, BJAB, LL58 and Ramos. No
evidence for GPR15 expression on Ramos, Raji, BCBL-1, LL58 and
DG75 cells was obtained, although the high levels of unspeciﬁc
antibody binding to Raji cells precluded a deﬁnite conclusion
regarding this cell line. In contrast, positive results were obtained
Fig. 1. SIVmac239 uses GPR15 with high efﬁciency for entry into transfected cells. (A) 293T cells were transfected with expression plasmids for CD4 and the indicated
coreceptors, both of human origin. At 48 h post transfection the cells were infected with HIV-1 pseudotypes bearing the indicated envelope proteins. Luciferase activities in
cell lysates were determined at 72 h post infection. The experiment was repeated twice and a representative experiment, performed in triplicates, is shown. Error bars
indicate standard deviations (SD). (B) 293T cells were transfected with the indicated coreceptors containing an N-terminal AU1 antigenic tag and expression was analyzed
by FACS employing anti AU-1 antibody. (C) The experiment was carried out as described for (A) except that the cells were infected with a replication competent SIVmac239
variant encoding luciferase or with env defective, luciferase-encoding SIVmac239 pseudotyped with VSV-G. The results7SD of a representative experiment carried out in
triplicates are shown and were conﬁrmed in a separate experiment. MLV, murine leukemia virus Env; 239, SIVmac239 Env; NL4-3; HIV-1 NL4-3 Env; VSV-G, vesicular
stomatitis virus G-protein; RLU, relative light units.
M. Kiene et al. / Virology 433 (2012) 73–84 75with NC37 B cells, indicating that certain T and B cell lines express
GPR15 on the cell surface.
Engineered expression of CCR5 rescues CEMx174 cell infection by
SIVmac239 variant P321S, which has a selective defect in GPR15
utilization
The cell line CEMx174 is frequently used for propagation of SIV
and we next asked if GPR15 expression is required for SIVmac239
infection of these cells. The SIVmac239 V3 loop mutant P321S
was previously shown by us to have a selective defect in GPR15
utilization (entry via CCR5 and CXCR6 was only slightly dimin-
ished) and in CEMx174 cell infection (Kirchhoff et al., 1997;
Po¨hlmann et al., 1999b). In order to ascertain that the reduced
CEMx174 cell infection by variant P321S was indeed due to
reduced usage of an alternative coreceptor, we analyzed if this
defect can be rescued by engineered expression of CCR5. For this,
we compared the ability of the SIVmac239 wt Env and P321S Env
to fuse with CEMx174 cells engineered to express CCR5
(CEMx174 R5) and with parental CEMx174 cells (CEMx174-SEAP,
(Means et al., 1997)), which are CCR5 (Kirchhoff et al., 1997).
CEMx174 R5 cells and CEMx174-SEAP cells harbor LTR-luciferase
and LTR-SEAP cassettes, respectively, which allow convenient
quantiﬁcation of cell–cell fusion. To measure cell–cell fusion,
293T effector cells were transiently cotransfected with Env
expression plasmids and an expression plasmid for the HIV-1NL4–3 Tat transactivator or an empty plasmid as control. The
effector cells were then cocultured with CEMx174 R5 cells or
CEMx174-SEAP cells and reporter activity in the cocultures was
measured. Robust activation of reporter gene expression was only
observed upon the presence of Tat and an Env protein in effector
cells, indicating that the signals speciﬁcally reﬂected cell–cell
fusion events, as expected (Fig. 3A). The wt Env protein mediated
robust fusion with both cell lines tested, in agreement with its
ability to use both CCR5 and GPR15 as coreceptors. In contrast,
the P321S Env mediated efﬁcient fusion with CEMx174 R5 cells
but not with CEMx174-SEAP cells, in accordance with the pre-
vious ﬁnding that this mutant can employ CCR5 but not GPR15 for
robust host cell entry (Po¨hlmann et al., 1999b) (Fig. 3A).
We next determined if the rescue of P321S mediated cell–cell
fusion by engineered expression of CCR5 is also reﬂected on the
level of virus–cell fusion. For this, HIV-1 pseudotypes bearing
MLV Env, SIVmac239 wt Env and P321S Env were normalized for
comparable infectivity on TZM-bl indicator cells and subse-
quently used for parallel infection of CEMx174-SEAP or CEMx174
R5 cells. In accordance with the cell–cell fusion data, the P321S
Env failed to mediate entry into CCR5-negative CEMx174-SEAP
cells but facilitated robust infection of CCR5-expressing CEMx174
R5 cells (Fig. 3B). In contrast, the SIVmac239 wt Env allowed
efﬁcient infection of both cell lines. Thus, the defect of the P321S
variant in mediating cell–cell and virus–cell fusion with parental,
CCR5-negative CEMx174 cells can be rescued by engineered
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Fig. 2. Lymphoid cell lines express GPR15. (A) Antibody speciﬁcity was tested by FACS staining of 293T cells transfected with the indicated coreceptors. At 48 h post
transfection the cells were stained with mIgG2b isotype control or GPR15-speciﬁc antibody and Cy5-conjugated anti-mouse secondary antibody. Staining was analyzed by
FACS and similar results were obtained in two separate experiments. (B) The T/B hybrid cell lines CEMx174 and CEMx174R5 as well as the T cell lines Jurkat, C8166-SEAP,
SupT1, CEM-T4, and PM-1, and the B cell lines Raji, Ramos, DG75, BJAB, BCBL-1, LL58 and NC37 were stained for surface expression of GPR15 as described in (A) after
blocking the cellular Fc receptors with human IgG or normal donkey serum. Staining was measured by FACS analysis. The experiment was repeated at least three times for
each cell line.
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alternative coreceptor, most likely GPR15.
shRNA knockdown of GPR15 in CEMx174 cells inhibits SIVmac239
infection
For direct evidence that GPR15 facilitates SIVmac239 infection
of CEMx174 cells, we performed short hairpin RNA (shRNA)
mediated knock-down (the anti-GPR15 antibody did not block
infection). To this end, a shRNA was identiﬁed that efﬁciently
reduced expression of transfected GPR15 but not CCR5 in 293T
cells (not shown). Subsequently, CEMx174 cells were electropo-
rated with a shRNA expression plasmid encoding either theGPR15-speciﬁc shRNA or a scrambled, non-sense control shRNA.
In addition to the shRNA, the plasmids encode for GFP, which
allowed convenient identiﬁcation of transfected cells. CEMx174
cells that had taken up plasmid encoding the GPR15-speciﬁc
shRNA showed reduced GPR15 expression compared to cells that
had received the plasmid encoding the control shRNA (Fig. 3C),
indicating speciﬁc GPR15 knock-down by the shRNA used. Due to
inefﬁcient delivery of plasmid DNA into CEMx174 cells (11% of
the cells were transfected, Fig. 3C), transfected and thus GFP-
positive cells were sorted by ﬂuorescence-activated cell sorting
(FACS) before infection with pseudotypes bearing the MLV Env or
the SIVmac239 Env. Infection of CEMx174 cells by MLV pseudo-
types was not modulated by GPR15 knock-down. In contrast,
Fig. 3. GPR15 is required for SIVmac239 entry into CEMx174 cells. (A) 293T effector cells were cotransfected with plasmids encoding HIV-1 Tat and SIVmac239 Env
(239wt) or SIVmac239 P321S Env, an envelope mutant that has a selective defect in GPR15 usage. The effector cells were then cocultured with CEMx174-SEAP target cells
(left panel), which are CD4þ , GPR15þ and CCR5 and contain a secreted alkaline phosphatase (SEAP) expression cassette under control of the viral LTR, or CEMx174 R5
target cells (right panel), which are CD4þ , GPR15þ and CCR5þ and contain a luciferase expression cassette under control of the viral LTR. Luciferase and SEAP-activity in
cocultures was measured at 48 h post cocultivation. The average of three independent experimens is shown. Error bars indicate standard error of the mean (SEM). (B)
CEMx174 or CEMx174 R5 cells were infected with HIV-1 pseudotypes bearing the indicated envelope proteins. Luciferase activities were measured 72 h post infection. The
experiment was repeated twice and the results of a representative experiment performed in triplicates are shown. Error bars indicate SD. (C) CEMx174 cells were
electroporated with plasmids encoding control shRNA (left dot plot) or GPR15-speciﬁc shRNA (right dot plot), stained for GPR15 expression and analyzed by FACS. The
shRNAs encoding plasmids also contain an expression cassette for GFP, allowing detection of transfected cells. (D) CEMx174 cells, sorted for expression of the GPR15-
speciﬁc shRNA (as judged by GFP expression), were infected with HIV-1 pseudotypes bearing the indicated envelope proteins. Luciferase activity in cell lysates was
determined at 72 h post infection. The experiment was repeated two times and a representative experiment, performed in triplicates, is shown. Error bars indicate SD. RLU,
relative light units.
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bearing the SIVmac239 Env (Fig. 3D). These results demonstrate
that SIVmac239 utilizes the alternative coreceptor GPR15 for
infection of the CCR5-deﬁcient T/B hybrid cell line CEMx174.
GPR15 is expressed on subsets of primary human T cells and B cells
We next explored if GPR15 is expressed on primary CD4þ
PBMCs, the major HIV and SIV target cell type. PBMCs were
isolated from whole blood of healthy human donors, cultivated in
the presence or absence of phytohemagglutinin (PHA) for 3 to 5
days and subjected to antibody staining for GPR15 surface
expression as described above. Additionally, PBMCs were co-
stained for either CD4, CD8 or CD19 to identify T cell and B cell
populations, respectively. An isotype matched antibody control
was included to determine the level of background staining.
Although ratios varied between donors, PHA-stimulated PBMC
populations consisted of approximately 80% CD4þ T cells and 10%
B cells (Fig. 4A), while unstimulated PBMCs were composed of
approximately 70% CD4þ T cells and 25% B cells. GPR15 expres-
sion on PBMCs was readily detectable independent of cellular
activation but varied between donors, ranging from approxi-
mately 2 to 25% of all stimulated PBMCs, with an average of 9%
(Fig. 4B). GPR15 expression appeared to be moderately higher on
unstimulated relative to stimulated PBMC (Fig. 4A). However,
unspeciﬁc binding of the isotype control antibody was also
increased and higher background levels could account for the
observed difference. Notably, a variable portion of the GPR15þ
PBMCs coexpressed CD4 (avg. 11%) or CD19 (avg. 26%), respec-
tively (Fig. 4A and B), suggesting that particular lymphocytesubsets are GPR15þ . The activation status of the PBMCs had no
major effect on GPR15 expression on these lymphocyte subsets
(Fig. 4A). In addition, a subset of the CD8þ cells among the
stimulated PBMCs also expressed GPR15 (avg. 6%), demonstrating
that GPR15 expression among T cells is not limited to the helper
cell compartment (Fig. 4C, unstimulated, CD8þ PBMCs could not
be unequivocally assessed because of high background staining).
Since CD4þ helper T cells are the main target cells for HIV and SIV
infection, we ﬁnally investigated which subsets of CD3þ CD4þ
cells expressed GPR15. We found that the coreceptor was mainly
expressed on central memory cells (CM) and to a lesser degree on
effector memory cells (EM), with substantial donor variability
(Fig. 4D). In contrast, naı¨ve T cells were largely GPR15 with the
exception of one donor (Fig. 4D). Thus, various lymphoid cells
express GPR15, including a subset of effector memory CD4þ T
cells, which are the preferential targets of R5-tropic HIV-1 and SIV
isolates (Gondois-Rey et al., 2002; Grivel et al., 2000; Mehandru
et al., 2004).
GPR15-positive human PBMCs are not efﬁciently infected by SIV
SIVmne, SIVmac and SIVrcm can infect PBMCs from human
donors homozygous for the D32 ccr5 allele (Forte et al., 2003;
Zhang et al., 2000), indicating that various SIVs can use alternative
coreceptors for infection of human PBMCs. We determined if
GPR15þ cells are targeted by SIVmac. PBMCs from ccr5 wt/wt,
D32/wt and D32/D32 donors were prepared, PHA-activated and
infected with replication competent SIVmac239 encoding GFP.
Infection efﬁciency (as determined by GFP expression) and GPR15
expression were subsequently analyzed by ﬂow cytometry.
Fig. 4. Subsets of primary human lymphocytes express GPR15. (A) PBMC were isolated from whole blood by Ficoll gradient centrifugation and were either stimulated with
PHA for 3 days (stimulated PBMC) or cultured in the absence of PHA for 3 days (unstimulated PBMC). Subsequently, cells were stained for surface expression of GPR15, as
described in Fig. 2A. Additionally, stimulated PBMC were co-stained with FITC-conjugated population markers anti-CD4 and anti-CD19 (or respective FITC-conjugated
isotype matched controls) to identify T and B cells. Staining was analyzed by ﬂow cytometry. The experiment was repeated 10 times for stimulated PBMCs and 3 times for
unstimulated PBMCs to compensate for donor variation. The results of a representative experiment are shown. (B) Donor variation of GPR15 expression on total stimulated
PBMC or CD4þ or CD19þ subsets. The percentage of GPR15þ cells in the respective subpopulation or total PBMC was plotted for 10 different donors to reﬂect the donor
dependence of GPR15 expression. (C) PBMC were isolated and stimulated as described in (A) and stained for surface expression of GPR15 and CD8. A representative
experiment is shown as dot plots in the upper panel and GPR15 expression on total PBMC or CD8þ cells is shown for 7 different donors in the lower panel. (D) PBMCs were
isolated from whole blood by Lymphoprep gradient centrifugation and directly costained for CD3, CD4, CCR7, CD45RA and GPR15. Cells were gated for CD3þ , CD4þ cells
and GPR15 expression on the subsets was analyzed via FACS. CM: central memory (CCR7þ , CD45RA), EM: effector memory (CCR7 , CD45RA), N: naı¨ve (CCR7þ ,
CD45RAþ). Expression was analyzed for eight different donors to account for donor variation.
M. Kiene et al. / Virology 433 (2012) 73–8478Infection of PBMCs by SIVmac239 was detectable independent of
the ccr5 genotype, as expected, although infection of D32/wt and
particularly D32/D32 PBMCs was reduced compared to wt/wtPBMCs (Fig. 5A). However, none of the infected cells expressed
GPR15, indicating that GPR15þ cells are unlikely to contribute to
SIVmac ampliﬁcation in CCR5 human PBMCs.
Fig. 5. GPR15þ and CXCR6þ human PBMCs are not preferentially infected by SIV. (A) PBMCs from human donors with the indicated ccr5 genotypes were isolated,
PHA stimulated and infected with replication competent SIVmac239 containing a nef-IRES-GFP cassette. At three days post infection, GPR15 and GFP expression were
analyzed by FACS. Similar results were obtained in two separate experiments. (B) Human PBMCs were isolated from 9 different donors, PHA stimulated for 3 to 5 days and
infected with GFP-encoding, SIVmac239 or SIVmac239/316Env bearing viruses. At three days post infection, expression of GPR15 and GFP was analyzed. The percentage of
the infected cells, which expressed GPR15, is shown. (C) Human PBMCs were isolated and stimulated with PHA for ﬁve days prior to infection with GFP encoding,
replication-competent SIVmac239 or SIVmac239/316Env, respectively. Three days post infection the expression of GPR15 and CXCR6 as well as GFP were analyzed by ﬂow
cytometry. Similar results were obtained in a separate experiment. (D) Human PBMCs were isolated, stimulated with PHA and infected with GFP-encoding HIV-1 NL4-3
(X4-tropic) or HIV-1 NL4-3 encoding the V3-loop of 92TH014-2 (R5-tropic) and stained for expression of GFP and GPR15. Similar results were obtained in two independent
experiments.
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M. Kiene et al. / Virology 433 (2012) 73–8480In order to analyze the susceptibility of GPR15þ cells to
SIVmac infection in more detail, we next examined infection of
PBMC from multiple donors, including individuals with a high
percentage of GPR15þ cells. In addition to SIVmac239 also
SIVmac239/316Env, a macrophage tropic variant of SIVmac239
(Mori et al., 1992), was used for these experiments, in order to
exclude envelope speciﬁc effects. Finally, we asked if infected
cells might express CXCR6, which facilitates SIVmac239 and
SIVmac239/316Env entry into transfected cells (Fig. 1 and
(Sharron et al., 2000)). Infection of GPR15þ cells by SIVmac239
Env bearing viruses was detectable in the majority of donors but
was generally inefﬁcient, with on average 13.673.1% of the
infected cells expressing GPR15 (Fig. 5B). Similar results were
obtained for SIVmac239/316Env, although infection of GPR15þ
cells was more efﬁcient (24.373.1% of the infected cells
expressed GPR15). Nevertheless, for a donor with high GPR15
expression up to 30% of the infected cells were GPR15þ and
roughly 40% were positive for CXCR6 (Fig. 5C), indicating that
GPR15þ and CXCR6þ cells could contribute to viral spread in
some individuals. In this context it should be noted that SIV-
mac239 infection only modestly reduced GPR15 expression on
CEMx174 R5 cells (20–40% reduction of geometric mean channel
ﬂuorescence), with all infected cells remaining in the GPR15þ
gate (not shown), indicating that efﬁcient coreceptor down-
regulation was unlikely to account for the absence of GPR15 on
the majority of the infected PBMCs. Finally, PBMCs infected by
GFP-encoding, X4- and R5-tropic HIV-1 were also largely devoid
of GPR15, indicating that GPR15þ cells are poorly susceptible to
HIV-1 infection (Fig. 5D). Thus, GPR15þ PBMCs are infected with
relatively low frequency by SIVmac and HIV-1 and are thus
unlikely to substantially contribute to viral ampliﬁcation.Discussion
SIV isolates frequently use GPR15 with similar efﬁciency as
CCR5 for infection of transfected cell lines (present study and
(Deng et al., 1997; Farzan et al., 1997)) but the role of endogenous
GPR15 in SIV cell tropism is largely unknown. We showed that a
subset of human T and B cell lines and primary human T and B
cells express GPR15 on the cell surface. Expression of GPR15 was
essential for SIVmac infection of the cell line CEMx174. In
contrast, GPR15þ PBMCs were not preferentially infected by
SIVmac, indicating a minor contribution of GPR15þ cells to
SIVmac ampliﬁcation in human PBMCs.
Shortly after the discovery of CCR5 as major coreceptor for HIV
and SIV it was appreciated that CCR5 expression does not account
for all aspects of SIV cell tropism. Subsequently, more than ten
alternative coreceptors were identiﬁed which supported HIV and/
or SIV infection, at least under conditions of high expression
(Choe et al., 1998; Deng et al., 1997; Dumonceaux et al., 1998;
Edinger et al., 1998a,b; Farzan et al., 1997; Kanbe et al., 1999;
McKnight et al., 1998; Neil et al., 2005; Rucker et al., 1997;
Shimizu et al., 1999). GPR15 and CXCR6 were shown to allow SIV
infection with high efﬁciency (Deng et al., 1997; Farzan et al.,
1997), a ﬁnding conﬁrmed by the present study, and CXCR6 was
subsequently demonstrated to be expressed on cell lines and
PBMCs susceptible to HIV and SIV infection (Sharron et al., 2000).
Similar studies were not conducted for GPR15, probably because
of the lack of a suitable reagent for detection of GPR15 expression.
A mouse monoclonal anti-GPR15 (IgG2b) antibody became
commercially available in the meantime and has been used in the
present study to characterize GPR15 expression on cell lines and
human PBMCs. The antibody reacted efﬁciently with GPR15
transfected cells but did not bind to CCR5, CXCR4, CXCR6, GPR1,
CCR2 and CCR3 transfected cells, indicating that the staining wasspeciﬁc for GPR15. GPR15 expression was detected on the T cell
line PM-1, the T/B cell hybrid CEMx174 and the B cell line NC-37.
In contrast, GPR15 was absent from Jurkat and Sup-T1 T cells,
which are known to be CD4þ , CXCR4þ , CCR5 and poorly, if at
all, susceptible to SIV infection (Del Prete et al., 2009; Lee et al.,
2001). PM-1 cells are commonly used to propagate HIV and SIV
and, due to their endogenous expression of CCR5 (Lusso et al.,
1995; Po¨hlmann et al., 1999b; Steinberger et al., 2000), coexpres-
sion of GPR15 might not be required for SIV infection of this cell
line. Indeed, the SIVmac239 variant P321S, which uses CCR5 but
not GPR15 for efﬁcient cellular entry (Kirchhoff et al., 1997;
Po¨hlmann et al., 1999b), was previously shown to replicate
efﬁciently in PM-1 cells but not in CEMx174 cells (Po¨hlmann
et al., 1999b), which are CD4þ , CCR5 and GPR15þ , as discussed
below. Intriguingly, the P321S variant also failed to replicate in
C8166 cells (Po¨hlmann et al., 1999b), an HTLV transformed
human T cell line susceptible to SIV infection (McKeating et al.,
1989), and only trace amounts of GPR15 were detected on these
cells. While these low levels of GPR15 might be sufﬁcient to allow
entry of wt SIV, it cannot be excluded that the P321S substitution
abrogates usage of GPR15 and one or more so far uncharacterized
coreceptors, which are engaged by wt SIV for infection of
C8166 cells.
The cell line CEMx174 and its derivatives CEMx174-SEAP and
CEMx174 R5 are frequently used for the propagation of SIV. An
early study demonstrated that this cell line is CD4þ , CCR5 but
expresses at this point an unknown coreceptor which is used by
wt SIVmac239 but not by the SIVmac239 V3 loop mutant P321S
(Kirchhoff et al., 1997). Subsequently, it was shown that GPR15
allows SIV infection of transfected cells and that endogenous
GPR15 is expressed in CEMx174 cells (Deng et al., 1997; Farzan
et al., 1997). However, it has not been demonstrated that GPR15 is
indeed used by SIV for infection of CEMx174 cells. We closed this
gap by two approaches. First, we demonstrated that the defect in
CEMx174 cell infection exerted by the substitution P321S can be
rescued by engineered expression of CCR5 (in CEMx174 R5 cells),
which conﬁrms that the P321S phenotype is due to lack of usage
of an alternative coreceptor. Second, we showed that shRNA-
mediated knock-down of GPR15 expression reduces virus–cell
fusion driven by the SIVmac Env but not the MLV Env. These
results demonstrate that SIVmac engages GPR15 for infection of
CEMx174 cells and provide, to our knowledge, the ﬁrst formal
demonstration that endogenous GPR15 exerts coreceptor function
for SIV.
Given the ability of endogenous GPR15 to support SIV entry
into CEMx174 cells, we next examined whether endogenous
GPR15 is expressed on primary human lymphoid cells. FACS
analysis demonstrated that a subset of CD4þ human PBMCs, the
major targets of HIV and SIV infection, indeed expresses GPR15.
Similarly, a portion of CD8þ and CD19þ PBMCs, respectively, was
found to be GPR15þ . However, variability between preparations
and donors were noted for at present unclear reasons. Differences
in the cellular activation status might play a role, although GPR15
expression was detected at roughly comparable levels on unsti-
mulated and PHA stimulated PBMCs. The phosphoinositide
3-kinase (PI3K)/protein kinase B (Akt) pathway was shown to
regulate GPR15 surface expression and activation of this pathway
might be donor dependent or might proceed with variable
efﬁciency under the culture conditions chosen (Chung et al.,
2009). Effector memory cells are preferentially depleted by
CCR5-tropic HIV and SIV (Mehandru et al., 2004; Spina et al.,
1997; Veazey et al., 2000a; Veazey et al., 2000b), while infection
with X4- or R5X4-dualtropic SIV/HIV hybrid viruses (SHIVs)
results in pan CD4þ T cell depletion (Grivel et al., 2000;
Nishimura et al., 2004). Our analysis of CD4þ T cell subsets
revealed that GPR15 is expressed on effector memory cells and
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was higher on central memory compared to effector memory
cells, while GPR15 was largely absent from naı¨ve CD4þ T cells.
How GPR15 expression is linked to the acquisition of the memory
phenotype remains to be established.
Homozygosity for the D32 ccr5 allele is associated with
marked resistance against sexually acquired HIV-1 infection
(Dean et al., 1996; Huang et al., 1996; Samson et al., 1996) and
a panel of R5-tropic viruses was found to be unable to replicate in
cultured PBMCs from ccr5 D32 homozygous donors, despite
efﬁcient usage of alternative coreceptors for entry into trans-
fected cells (Zhang et al., 2000; Zhang et al., 2001). Although
evidence for infection of ccr5 D32/D32 PBMCs was reported by
some studies (Cilliers et al., 2005; Jiang et al., 2011; Willey et al.,
2003), these results indicate that most HIV-1 isolates cannot use
alternative coreceptors for infection of PBMCs. In stark contrast,
various SIV and some HIV-2 isolates were shown to infect ccr5
D32/D32 PBMCs in the absence of CXCR4 usage (Forte et al., 2003;
Willey et al., 2003; Zhang et al., 2000), indicating that these
viruses can use alternative coreceptors for entry into PBMCs.
However, the identity of the responsible alternative coreceptors
remained largely unclear. Our analysis of infected PBMCs from
multiple donors demonstrates that GPR15þ cells are targeted by
SIVmac239 with low efﬁciency, independent of the ccr5 genotype,
indicating that lack of functional CCR5 on target cells does not
skew infection towards GPR15þ cells. Nevertheless, when analyz-
ing PBMCs from a donor with a high proportion of GPR15þ cells,
roughly 30% of the infected cells were positive for GPR15 and 40%
expressed CXCR6, which is used with similar efﬁciency as GPR15
for SIV entry into transfected cells (Deng et al., 1997; Farzan et al.,
1997). Similar results were obtained with a macrophage tropic
variant of SIVmac239, SIVmac239/316Env (Mori et al., 1992), in
agreement with the previously reported SIV infection of CXCR6þ
PBMCs (Sharron et al., 2000). Thus, a fraction of the GPR15þ and
CXCR6þ cells in human PBMC preparations can be susceptible to
SIVmac infection, although they do not constitute preferred viral
targets. Finally, infection of GPR15þ cells by X4- and R5-tropic
HIV-1 was inefﬁcient, suggesting that the contribution of GPR15þ
cells to the ampliﬁcation of HIV-1 in human PBMCs is minor.
While our results argue against an important role of GPR15 in
the hematogenic spread of HIV-1 and SIV they clearly do not
exclude a role of this coreceptor in viral pathogenesis. In fact,
recent studies revealed that GPR15 might be involved in enter-
ocyte (Clayton et al., 2001; Li et al., 2008; Maresca et al., 2003)
and neutrophil (Elbim et al., 2008) apoptosis in the context of
HIV-1 and SIV infection, indicating that HIV/SIV interactions with
GPR15 merit further analysis.Material and methods
Cell culture
The human embryonal kidney cell line 239T and TZM-bl cells
(obtained from the NIH AIDS Research and Reference Reagent
Program, #8129) were cultured in DMEM (Invitrogen) containing
10% fetal calf serum (FCS) and antibiotics penicillin/streptomycin.
CEMx174 (Salter et al., 1985), CEMx174-SEAP (Means et al.,
1997), CEMx174 R5 (Hsu et al., 2003), C8166-SEAP (Means
et al., 1997), Jurkat, SupT1, CEM-T4, PM-1, LL58, Raji, Ramos,
NC37, BCBL-1, DG75, and BJAB cells were cultured in RPMI 1640
(PAA) containing 10% FCS and antibiotics penicillin/streptomycin.
Peripheral blood mononuclear cells (PBMC) were isolated via
Ficoll (Biomol) or Lymphoprep (Axis shield PoC As) gradient
centrifugation and were cultured in RPMI 1640 (PAA) containing
10% FCS and antibiotics penicillin/streptomycin supplementedwith 100 units/ml interleukin-2 (IL-2, Roche). Prior to infection
PBMC were stimulated with 5 mg/ml phytohemagglutinin (PHA,
Sigma-Aldrich) for 3 days.
Plasmids
The plasmids encoding wt SIVmac239 and SIVmac239 variants
containing a nef IRES GFP cassette or the luciferase gene in place of
nef were described previously (Laguette et al., 2012; Po¨hlmann et al.,
2001). The SIVmac239/316Env variant encoding a nef-IRES-GFP
cassette was generated by insertion of a vpx–vpr–env fragment
derived from pSIVmac316 (Mori et al., 1992) into pBRSIVmac239_-
nefþ_IRES_eGFPd5 (Laguette et al., 2012). The presence of the 316
mutations was conﬁrmed by sequence analysis. The plasmids encod-
ing HIV-1 NL4–3 (X4-tropic) and HIV-1 NL4–3 with the V3 loop of
92TH014–2 (R5-tropic), both encoding EGFP in place of nef, were
described previously (Chaipan et al., 2010; Papkalla et al., 2002). The
HIV-1 NL4–3 RE Luc lentiviral vector (Connor et al., 1995), the
plasmids encoding MLV env, HIV-1 NL4–3 env, SIVmac239 env, and
SIVmac239 P321S env (Po¨hlmann et al., 1999b; Simmons et al., 2003)
and the plasmids encoding CCR2, CCR3, CCR5, CXCR4, CXCR6, GPR1,
and GPR15 were also previously described (Po¨hlmann et al., 1999a;
Po¨hlmann et al., 1999b; Po¨hlmann et al., 2000) or were obtained via
the NIH AIDS Research and Reference Reagent Program. For shRNA-
mediated GPR15 knock-down, the oligonucleotides 5-siGPR15-pos48-
BamHI/MluI GATCCAGCCCAAACTCTGACATCATTCAAGAGATGATGT-
CAGAGTTTGGGCTTTTTTTACGCGTG and 3-siGPR15-pos48-EcoRI/MluI
AATTCACGCGT AAAAAAAGCCCAAACTCTGACATCATCTCTTGAATGAT-
GTCAGAGTTTGGG were annealed and inserted into pSirenRetro-
Q-EGFP (Clontech) employing the BamHI/EcoRI restriction sites. The
following oligonucleotides were used to generate coreceptors with
N-terminal AU1-antigenic tag: p5-CCR5-AU1-HindIII CCCAAGCTT-
CACCATGGACACCTACAGATACATAGATTATCAAGTGTCAAGAATCTATG
and p3-CCR5-XbaI CCTCTAGACCTCACAAGCCCAC;AGATATTTC (for
construction of AU1 tagged CCR5), p5-GPR15-AU1-HindIII CCAAG-
CTTCACCATGGACACCTACAGATACATAGACCCAGAAGAAACTTCAGTTT-
ATTTGG and p3-GPR15-XbaI CCTCTAGACCTTAGAGTGACACAGACCT-
CTTCC (for construction of AU1 tagged GPR15) and p5-CXCR6-AU1-
HindIII CC AAGCTTCACCATGGACACCTACAGATACATAGCAGAGCATG-
ATTACCATGAAGACTATGG and p3-CXCR6-XbaI CCTCTAGACCCTAT-
AACTGGAACATGCTGG (for construction of AU1 tagged CXCR6)
ccr5 genotyping
For the determination of the ccr5 genotype, mucosal epithelial
cells were collected, washed with PBS, pelleted and treated with
proteinase K for 60 min at 56 1C. Subsequently, the enzymatic
activity was inactivated by incubation of the samples at 95 1C for
15 min. Finally, the ccr5 sequence was ampliﬁed employing
primers 5-CCR5del32 CCC AGG AAT CAT CTT TAC CAG and
3-CCR5del32 CCC AGA AGA GAA AAT AAA CAA TCA T (Kantarci
et al., 2005) and reaction products were analyzed by agarose gel
electrophoresis.
FACS staining
For analysis of GPR15 expression on cell lines, a total number
of 2105 cells were washed with FACS buffer (1x PBS supple-
mented with 5% FCS), blocked for 30 min with 10 ml human IgG
(Miltenyi Biotech) or 20 ml normal donkey serum (Sigma), and
stained with mouse anti-GPR15 or anti-CXCR6 antibody (R&D
Systems) or matched mIgG2b isotype control antibody diluted
1:50 in FACS buffer for 30 min at 41C. The cells were washed again
and stained with anti-mouse Cy5 (1:100) or anti-mouse
Dylight649 (1:250) (Dianova) secondary antibody in FACS buffer
for 30 min at 41C, followed by washing and ﬁxation in PBS/2%
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above and for CD4, CD8 and CD19 using directly labeled FITC-
conjugated mouse monoclonal antibodies or the respective iso-
type matched controls (BD Biosciences). The cell staining was
analyzed via FC500 cytometer (Beckman Coulter) and FCS Express
(De Novo Software) or FlowJo (Tree Star) software. For subpopu-
lation analysis GPR15 staining on CD4þ cells was performed as
described above, but in this case directly ex vivo without any
blocking using anti-mouse Dylight 649 (Dianova) secondary anti-
body diluted 1:250 in FACS buffer and anti-CD3 V450, anti-CD4
PE, anti-CD45RA PE-Cy5.5, anti-CCR7 PE-Cy7 (BD Biosciences).
The staining was analyzed via LSRII (BD Biosciences) and FlowJo
(Tree Star) software.
Cell–cell fusion assay
293T cells were seeded at a density of 1.3105 cells/ml in a
12-well plate. After 16 h cells were transfected with 1.5 mg of
plasmid encoding SIVmac239 env and 1.5 mg of plasmid encoding
the ﬁrst exon of SIVmac239 tat using the calcium phosphate
transfection method. At 24 h post transfection cells were mixed
with 1105 cells/ml CEMx174-SEAP or CEMx174R5 cells con-
taining a secreted alkaline phosphatase (SEAP) or ﬁreﬂy luciferase
expression cassette, respectively, under the control of a truncated
SIV long terminal repeat (LTR) promoter. At 48 h post mixing of
cells, SEAP activity in culture supernatants or luciferase activity in
cell lysates were measured using the PhosphaLight assay system
(Applied Biosystems) or the Beetle-Juice ﬁreﬂy luciferase assay
system (PJK), respectively.
Virus production
Viruses were produced as described previously by us (Po¨hlmann
et al., 2007; Simmons et al., 2003). In brief, 293T cells were seeded
in T-25 culture ﬂasks at 7.5105 cells per ﬂask. After 16 h cells
were transfected with either 12 mg of full-length SIVmac239
or SIVmac239/316Env proviral plasmid DNA or cotransfected
with 6 mg of HIV-1 NL4–3 ERLuc plasmid DNA and 6 mg of
envelope protein expression plasmids or empty vector (for
production of pseudotypes) using the calcium phosphate trans-
fection protocol. The transfection medium was replaced by fresh
culture medium at 8–14 h post transfection. Culture supernatants
were harvested at 48 h post transfection, separated from cell
debris via ﬁltration through a 0.445 mm pore size ﬁlter, aliquotted
and stored at 80 1C. Virus stocks were normalized for compar-
able infectivity in TZM-bl cells.
Infection experiments
293T cells transfected to express CD4 and one of the corecep-
tors were seeded 24 h prior to infection at 1104 cells/well and
CEMx174-SEAP and CEMx174 R5 cells were seeded at 2104
cells/well in 96-well plates and infected with HIV-1 NL4–3
ERLuc pseudotyped with MLV, HIV-1 NL4–3, SIVmac239 or
SIVmac239 P321S envelope proteins which were normalized for
comparable infectivity on TZM-bl cells. At 8 h post infection the
medium was replaced by fresh culture medium. SEAP activity in
culture supernatants or luciferase activity in cell lysates were
measured 72 h post infection using the PhosphaLight assay
system (Applied Biosystems) or the Beetle-Juice ﬁreﬂy luciferase
assay system (PJK), respectively.
shRNA knock down of GPR15 and infection with pseudovirus
A total number of 1107 cells/ml CEMx174 cells were elec-
troporated with 20 mg of plasmids encoding GPR15 speciﬁc orcontrol shRNA and a GFP expression cassette (pSiren RetroQ,
Clontech). At 24 h post electroporation CEMx174 cells were
sorted for GFP-positive (¼shRNA-positive) cells using a FACSAria
(BD Biosciences) or MoFlo (Beckman Coulter) cell sorter. Sorted
cells were then seeded at 3104 cells/well in 96 well plates and
spinoculated (O’Doherty et al., 2000) with HIV-1 NL4–3 ERLuc
pseudotyped with SIVmac239 or MLV Env proteins for 2 h at
2000 rpm at room temperature. At 8 h post infection the medium
was replaced by fresh culture medium. Luciferase activities in cell
lysates were measured at 72 h post infection using the Beetle-
Juice ﬁreﬂy luciferase assay system (PJK).
PBMC infection with SIVmac239-GFP virus
Prior to infection PBMC were stimulated with 5 mg/ml phyto-
hemagglutinin (PHA) and 100 units/ml interleukin-2 (IL-2) for
3–5 days and then seeded for infection at 5105 cells/well in a
24-well plate. For infection the culture medium was removed and
cells were resuspended in culture medium containing GFP-coding
SIVmac239 or SIVmac239/316Env, respectively. Alternatively,
cells were infected with GFP-encoding, env-defective HIV-1
bearing the Env protein of SIVmac239 or SIVmac239/316Env.
After incubation at 37 1C for 8 h, the medium was replaced by
fresh culture medium and 72 h post infection the cells were
analyzed by ﬂow cytometry for GPR15, CXCR6 and GFP expres-
sion. After gating, at least 100,000 events were counted.Acknowledgments
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